Literature DB >> 6304481

The relative infrequency and low levels of neutralising and immunoprecipitating antibody to herpes simplex viruses types 1 and 2 in patients with a history of recurrent herpes genitalis.

C B Woodman, D Stocker, D Sugrue, M Desberbasques, C E Hartley, A Fuller, A Buchan, G R Skinner.   

Abstract

Twenty-seven per cent of 70 patients with a history of recurrent herpes genitalis but no concomitant history of recurrent oral or peri-genital disease, had no detectable neutralising antibody against type 1 or type 2 herpes simplex virus; the prevalence and levels of neutralising antibody were similar to 53 patients with no history of herpetic disease and significantly lower than 67 patients with a history of recurrent herpes genitalis in association with oral or peri-genital disease all of whom had neutralising antibody against both virus types. There were similar differences between groups for immunoprecipitating antibody where 80% of patients were herpes genitalis alone had no detectable immunoprecipitating antibody. The results indicate that the failure to detect immunising and immunoprecipitating antibody in an individual's serum is compatible with a long and even severe history of recurrent herpes genitalis and consequently that the development of neutralising antibody does not necessarily indicate an episode of primary herpetic disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304481     DOI: 10.1007/bf02123498

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  19 in total

1.  Serological relatedness of herpes simplex viruses. Type-specificity of antibody response.

Authors:  G R Skinner; M E Thouless; S Trueman; J Edwards; A J Gibbs
Journal:  Immunology       Date:  1976-09       Impact factor: 7.397

2.  Comparative analyses of the proteins and antigens of five herpesviruses.

Authors:  R A Killington; J Yeo; R Honess; D H Watson; B E Duncan; I W Halliburton; J Mumford
Journal:  J Gen Virol       Date:  1977-11       Impact factor: 3.891

3.  Antibodies to genital herpesvirus in patients with carcinoma of the cervix.

Authors:  W E Rawls; H L Gardner; R L Kaufman
Journal:  Am J Obstet Gynecol       Date:  1970-07-01       Impact factor: 8.661

4.  A serologic study of herpesvirus hominis strains by microneutralization tests.

Authors:  F P Pauls; W R Dowdle
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

5.  Seroepidemiologic studies of herpesvirus type 2 and carcinoma of the cervix. IV. Dysplasia and carcinoma in situ.

Authors:  E Adam; R H Kaufman; J L Melnick; A H Levy; W E Rawls
Journal:  Am J Epidemiol       Date:  1973-08       Impact factor: 4.897

6.  Antibodies to type 1 and type 2 herpes virus in women with abnormal cervical cytology.

Authors:  G R Skinner; M E Thouless; J A Jordan
Journal:  J Obstet Gynaecol Br Commonw       Date:  1971-11

7.  Preparation and immunogenicity of vaccine Ac NFU1 (S-) MRC towards the prevention of herpes genitalis.

Authors:  G R Skinner; C B Woodman; C E Hartley; A Buchan; A Fuller; J Durham; M Synnott; J C Clay; J Melling; C Wiblin; J Wilkins
Journal:  Br J Vener Dis       Date:  1982-12

8.  Detection of type-specific antibody to herpes simplex virus type 1 and 2 in human sera by complement-fixation tests.

Authors:  G R Skinner; C H Hartley; J E Whitney
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

9.  Early experience with "antigenoid" vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis.

Authors:  G R Skinner; C Woodman; C Hartley; A Buchan; A Fuller; C Wiblin; G Wilkins; J Melling
Journal:  Dev Biol Stand       Date:  1982

10.  Cell-mediated immunity in herpes simplex virus-infected mice: suppression of delayed hypersensitivity by an antigen-specific B lymphocyte.

Authors:  A A Nash; P G Gell
Journal:  J Gen Virol       Date:  1980-06       Impact factor: 3.891

View more
  5 in total

1.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  Augmentation of the neutralisation test for type 1 HSV: evidence of high representation of neutralising antibody in the adult community.

Authors:  P J Holmes; J A Hallworth; D I Stocker; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

3.  Humoral antibody response in patients with herpes genitalis: analysis of factors influencing the pattern of disease.

Authors:  J A Hallworth; D I Stocker; D Shariff; D Sugrue; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

4.  Efficacy of vaccine Ac NFU1 (S-) MRC 5 given after an initial clinical episode in the prevention of herpes genitalis.

Authors:  C B Woodman; A Buchan; A Fuller; C Hartley; G R Skinner; D Stocker; D Sugrue; J C Clay; G Wilkins; C Wiblin
Journal:  Br J Vener Dis       Date:  1983-10

5.  B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin.

Authors:  Emily S Ford; Anton M Sholukh; RuthMabel Boytz; Savanna S Carmack; Alexis Klock; Khamsone Phasouk; Danica Shao; Raabya Rossenkhan; Paul T Edlefsen; Tao Peng; Christine Johnston; Anna Wald; Jia Zhu; Lawrence Corey
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.